Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus

Darren K McGuire, Jeffrey R. Winterfield, Jason A. Rytlewski, Ele Ferrannini

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Type 2 diabetes mellitus (DM) is increasing around the world, and the public health impact of DM, driven largely by cardiovascular disease complications, underpins the importance of continued efforts toward primary prevention of DM. Only a few interventions have been shown to prevent DM, with none of them yet proven to improve cardiovascular risk commensurately. Accumulating evidence suggest that drugs that block the renin-angiotensin- aldosterone system (RAAS), many of which have proven cardiovascular disease (CVD) benefit, also have favourable effects on parameters of glucose metabolism and incident diabetes. Here we review the evidence accumulated to date from animal studies, clinical mechanistic studies and clinical trials regarding the effect of RAAS inhibition and incident DM.

Original languageEnglish (US)
Pages (from-to)59-66
Number of pages8
JournalDiabetes and Vascular Disease Research
Issue number1
StatePublished - Mar 2008


  • Angiotensin receptor blocker (ARB)
  • Angiotensin-converting enzyme (ACE) inhibitor
  • Diabetes
  • Prevention
  • Renin-angiotensin-aldosterone system

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus'. Together they form a unique fingerprint.

Cite this